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ABSTRACT

Introduction: Esthesioneuroblastoma (EBN) is a rare and malignant tumor of olfactory epithelium. Due to its infrequency, 
there are several controversies regarding its treatment, being the endoscopic approach a new option. Objective: 
describe a young male case of EBN, its challenging diagnosis and options of treatment. Case report: 21 year old man 
who presented with a two month history of difficulty breathing and hyposmia after undergoing nasal vein cauterization for 
recurrent epistaxis. Physical examination confirmed a mucosal mass obstructing his left nostril. Magnetic Resonance 
Imaging of the face demonstrated a mass within the nasal septum infiltrating the oropharynx, hard palate, cribriform 
plaque and orbital lamina of the ethmoid bone. Endovascular embolization was performed followed by transsphenoidal 
endoscopic surgical excision. Anatomopathological and immunohistochemistry analysis confirmed the diagnosis of EBN. 
Repeat MRI-face showed a residual lesion requiring open craniotomy in addition to radio-chemotherapy. Conclusion: 
EBN is an uncommon malignant tumour arising in the superior aspect of nasal cavity. There is no consensus regarding 
optimal treatment strategies. Endoscopic transsphenoidal resection is reserved to early stages only and its use on 
advanced disease has been poorly explored.





Introdução: Esthesioneuroblastoma (EBN) é uma neoplasia maligna rara do epitélio olfativo. Devido à sua raridade, há 
varias controvérsias quanto ao seu tratamento, sendo os avanços endoscópicos uma nova opção terapêutica. Objetivo: 
descrever o caso de um jovem masculino diagnosticado com EBN, a dificuldade diagnóstica e opções terapêuticas. 
Relato de Caso: masculino, 21 anos, apresentava há 2 meses dificuldade respiratória e hiposmia após ser submetido a 
cauterização de veia nasal devido a epistaxe recorrente. Ao exame foi confirmado massa nasal obstruindo narina 
esquerda. Ressonância magnética de face demostrou massa em septo nasal infiltrando orofaringe, palato, placa 
cribiforme e lâmina orbital do osso etmoide. Realizada embolização endovascular seguida de excisão cirúrgica 
endoscópica transesfenoidal. Anátomopatologia e imunohistoquímica confirmaram o diagnóstico de EBN. RNM pós-
operatória demostrou lesão residual. Realizada craniotomia aberta em associação com radio e quimioterapia. 
Conclusão: EBN é um tumor maligno incomum da cavidade nasal superior. Por isso, não há consenso em relação à 
melhor abordagem cirúrgica de tratamento. Ressecção endoscópica transesfenoidal deve ser reservada apenas para 
estágios iniciais e seu uso em doença avançada ainda não foi profundamente estudado. 
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INTRODUCTION 
The differential diagnosis of nasal masses is 
broad, comprising a large variety of benign and malignant 
aetiologies. The masses may represent a primary 
pathology as well as a sign of systemic comorbidities1. 
Congenital midline nasal masses (CMNMs) are an 
important group of primary nasal masses that usually 
present on early stages of life, even though a small 
fraction can be recognized until adulthood. The most 
common CMNMs are dermoid tumours, haemangiomas, 
nasal gliomas and encephaloceles. Tumours originated 
from neuroendocrine and neuroectodermal epithelium 
may occasionally present as CMNMs. Among these, 
neuroblastomas are the most common, particularly  in 
young males2. Esthesioneuroblastoma (EBN) is an 
uncommon malignant tumour arising in the superior wall 
of nasal cavity, representing 3-5% of all malignant nasal 
tumours. Since first described in 1924, around 1000 
cases have been reported in the literature worldwide2,3. 
There is no consensus regarding optimal treatment 
strategies. Most reports in the literature describe single 
institution experience with limited number of cases. 
Advances in endoscopic therapies have opened a new 
option to manage patients with this rare condition. 

CASE REPORT 
A twenty one year old gentleman presented for 
evaluation due to a 2 month history of difficulty breathing 
and hyposmia. Past medical history was unremarkable 
without prior surgeries or hospitalizations. Family history 
was negative for cancer or coagulopathies. Non-smoker, 
he denied alcohol and illicit drug use. 

Two months earlier, he presented to a local 
emergency department with a 4 month history of 
intermittent episodes of epistaxis and underwent 
electrical cauterization of the left nasal vein. Since then 
he had no new episodes of epistaxis. Nevertheless, he 
noticed progressive swelling of the left nostril associated 
with difficulty breathing and decrease in the capacity to 
detect different odors. Furthermore, he endorsed 
constant and progressively worsening frontal headache, 
minimally responsive to non-steroidal medications and 
acetaminophen. The headache would not be worsened 
by light or noise, and was not associated with nausea or 
vomiting.  He denied fevers, chills, skin rashes, 
abdominal pain or changes in urine pattern. 

On physical examination, patient was in no 
acute distress and no abnormalities on pulmonary 
auscultation. Neurologic examination showed no sensory 
or motor deficits, with normal evaluation of cranial nerves 
II-XII. Head, nose and ears examination was remarkable 
for a mucosal mass obstructing his left nostril. There was 
also tenderness to palpation of left frontal bone 
surrounding his left orbit. There was no conjunctival 
drainage or erythema. Right nostril was patent without 
signs of local infiltration. Fundoscopic examination was 
normal.

Initial laboratory evaluation including complete 
blood count, electrolyte panel and liver enzymes was 
within normal limits. Antinuclear (ANA) and antineutrophil 
cytoplasmic antibodies (ANCA) were negative. Magnetic 
resonance imaging (MRI) of the face demonstrated a 
contrast enhanced 8 x 6 x 2.4 cm solid lesion on the left 
nasal cavity with close contact with the nasal septum 
(Figure 1A and 1B). The mass extended posteriorly to the 
oropharynx, inferiorly to the hard palate, infiltrating the 
cribriform plaque superiorly and laterally penetrating the 
orbital lamina of the ethmoid bone. The lesion was 
surgically excised, as described on the treatment section 
below, and sent for anatomopathological analysis. Final 
biopsy results showed poorly differentiated neoplasia 
with features suggestive of esthesioneuroblastoma 
(F igu re 2A ) . Immunoh is tochemis t r y ana l ys i s 
demonstrated CD56, vimentin and synaptophysin 
positive tissue, confirming the diagnosis of olfactory 
neuroblastoma (Figure 2B). After the diagnosis of 
esthesioneuroblastoma was confirmed, patient 
underwent endovascular embolization of invasive 
intracranial lesion followed by transsphenoidal 
endoscopic surgical excision of the nasopharyngeal 
mass. 

A repeat MRI of the face showed a residual 1 x 
0.7 cm contrast enhancing lesion on the lateral nasal 
fossa (Figure 1C). In order to reassess and widen the 
surgical margins the patient was submitted to an open 
craniotomy. The second procedure was complicated with 
face cellulitis on postoperative day 20 with purulent 
drainage on the surgical incision. In addition to 
intravenous antibiotic therapy, a third surgical procedure 
was performed to optimize control of the infection site. 

External radiotherapy directed to the nasal 
fossa, maxillary and sphenoid sinuses was initiated four 
months following the initial surgical interventions. This 
was followed by five cycles of chemotherapy with 
ifosfamide and etoposide. One month following the 
initiation of radio-chemotherapy, the patient presented 
complaining of nasal xantochromic drainage. A CT-head 
demonstrated a laminar collection underneath the frontal 
bone plaque. Patient was diagnosed with osteomyelitis 
requiring bifrontal craniotomy and antibiotic therapy.

Patient completed all additional cycles of radio-
chemotherapy without further complications. Computed 
tomography (CT) of the head after completion of therapy 
was normal, without any remnant of the lesion. He is 
scheduled to return for reconstructive prosthesis of the  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Figure 1: MRI Brain pre and post transsphenoidal 
resection - Images A and B demonstrate an 8x6x2.4 
cm solid mass occupying the left nasal cavity. Image C 
demonstrates postoperative changes with a residual 
1x 0.7 cm contrast-enhancing lesion on the lateral 
nasal fossa. 
Figure 2: Anatomopathological and immunohistochemistry analysis - Image A shows small atypical neoplastic 
cells invading the surrounding connective tissue (Magnification 100x). Image B is part of immunohistochemistry 
analysis demonstrating strong positivity for synaptophysin (magnification 400x). 
frontal skull and continues follow-up with oncology every 
3 months without signs of recurrence.

DISCUSSION 
EBN is an uncommon malignant tumour arising 
in the superior aspect of nasal cavity that frequently 
invade orbit, skull base and even intracranial 
structures4,5. Initial symptoms are mostly nonspecific and 
can include nasal obstruction, epistaxis and hyposmia. 
Symptoms can mimic other benign inflammatory or 
infectious diseases. Thus, diagnosis delay is not 
uncommon6. Additional symptoms can be present 
depending on the site and stage of invasion of the 
tumour, evidenced in our case by severe frontal 
headache due to intracranial invasion through the left 
orbit7.

Incidence peaks bimodally in 11-20 and 50-60 
years; however, age may range from 3 to 88 years with 
no sex predilection, or a slight female predominance7,8. 
Even though it is usually unilateral, there are reports of 
bilateral cases8. Local recurrence occurs in up to 57% of 
cases and metastasis has been reported to happen 
between 20-60% of affected individuals, most commonly 
to cervical lymph nodes, parotid glands, skin, lungs, 
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bone, liver, orbit and spinal cord8. The present patient 
presented on an uncommon age group with already signs 
of locally invasive disease, which made the initial 
diagnosis challenging. 

The diagnosis is usually established through 
anatomopathological evaluation, which reveals 
homogenous small cells with uniform round to oval nuclei 
demonstrating rossete or pseudorossete formation in 
addition to eosinophilic fibrillary intercelular background 
material. Tumours may also be S100 positive. Following 
confirmation by biopsy, assessment of local extension 
with CT and/or MRI is necessary6,9. CT images are 
essential for correct staging. MRI enables a better 
estimate of tumor spread surrounding soft tissue areas9. 
Based on imaging findings, tumors are staged using the 
Kadish grading criteria in one of four categories:  Group 
A, which comprises tumors limited to the nasal fossa; 
Group B, in which tumors extend to the paranasal 
sinuses; Group C, with tumor extension beyond the 
paranasal sinuses, such as in the present case; and 
Group D, with evidence of distant metastasis3,10.

Several benign and malignant conditions can 
present as intranasal masses. Among malignant causes, 
alongside with EBN, other neuroendocrine and 
neuroectodermal neoplasms of the sino-nasal tracts 
should be considered in light of their similar embryonic 
origin to EBN. Table 1 summarizes some of the diagnosis 
considered in the present case prior to final pathological 
analysis1.

Table 1: Differencial diagnosis for intranasal masses 
Standard therapy for EBN consists in surgical 
resection followed by chemo and radiotherapy. Long 
term effective control can be achieved when neoadjuvant 
therapy is combined with aggressive surgical resection2,3. 
A n e w e n d o s c o p i c m o d a l i t y w i t h a p u re l y 
transsphenoidal approach has been recently introduced 
among the surgical resection options for this patient 
population11. In addition to being minimally invasive, the 
technique also improves exposure to the sphenoid sinus, 
orbital apex and nasopharynx when compared to 
craniofacial resection. Nevertheless, not all patients are 
candidates to this new approach. Restrictions include 
involvement of facial soft tissues, high vascularization, 
lateral extension over the orbital or for extensive 
intracranial invasion11,12. Therefore, most centers reserve 
endoscopic resection for patients with lower Kadish 
grades. The endoscopic approach in the present case 
was unique in light of his initial high grade staging 
(Kadish C). Even though a second MRI had shown signs 
of residual disease that lead to a second resection, 
patient remains without further signs of recurrence. 

In accordance to the literature, small cohorts 
studies have shown that the use of an endoscopic 
approach to patients with Kadish stage C or D disease 
can be effective in small cohorts13. One of the reasons of 
utilizing this technique on the present case was that it 
would allow reasonable exposure of the cavity minimizing 
complications, such as osteomyelitis, which did end up 
occurring following the second resection which used the 
traditional open approach. 

Studies shows that monitoring beyond the 
standard 5 year period is necessary10. Survival rates for 
combined therapy, traditional surgery and radiotherapy 
are 72.5%, 62.5% and 53.8%, respectively10,12,14. 
Survival following endoscopic resection, especially in the 
setting of higher Kadish grades, remains undetermined. 
Further studies with larger numbers of patients are 
necessary to assess the real role of this technique in 
patients with advanced disease. For that purpose, 
multicentre studies may be necessary in light of the low 
EBN incidence rates. Therefore, decision of the optimal 
surgical resection should be made in a case by case 
setting based on the extension of the disease, provider 
experience and patient preference in order to prevent 
recurrence and complications. 
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